-
Randomized Controlled Trial Multicenter Study
Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial.
- Savannah C Partridge, Zheng Zhang, David C Newitt, Jessica E Gibbs, Thomas L Chenevert, Mark A Rosen, Patrick J Bolan, Helga S Marques, Justin Romanoff, Lisa Cimino, Bonnie N Joe, Heidi R Umphrey, Haydee Ojeda-Fournier, Basak Dogan, Karen Oh, Hiroyuki Abe, Jennifer S Drukteinis, Laura J Esserman, Nola M Hylton, and ACRIN 6698 Trial Team and I-SPY 2 Trial Investigators.
- From the Department of Radiology, University of Washington, 825 Eastlake Ave E, G2-600, Seattle, WA 98109 (S.C.P.); Department of Biostatistics (Z.Z.) and Center for Statistical Sciences (Z.Z., H.S.M., J.R.), Brown University, Providence, RI; American College of Radiology Imaging Network (ACRIN), Reston, Va (Z.Z., H.S.M., J.R.); Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, Calif (D.C.N., J.E.G., B.N.J., L.J.E., N.M.H.); Department of Radiology/MRI, University of Michigan, Ann Arbor, Mich (T.L.C.); Department of Radiology, University of Pennsylvania, Philadelphia, Pa (M.A.R.); Department of Radiology, Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, Minn (P.J.B.); American College of Radiology and ECOG-ACRIN Cancer Research Group, Reston, Va (L.C.); Department of Radiology, University of Alabama, Birmingham, Birmingham, Ala (H.R.U.); Department of Radiology, University of California, San Diego, San Diego, Calif (H.O.); Department of Radiology, University of Texas MD Anderson Cancer Center, Houston, Tex and the University of Texas Southwestern Medical Center, Dallas, Tex (B.D.); Department of Radiology, Oregon Health and Science University, Portland, Ore (K.O.); Department of Radiology, University of Chicago, Chicago, Ill (H.A.); and Department of Diagnostic Radiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Fla and Department of Women's Imaging, St Joseph's Women's Hospital, Tampa, Fla (J.S.D.).
- Radiology. 2018 Dec 1; 289 (3): 618-627.
AbstractPurpose To determine if the change in tumor apparent diffusion coefficient (ADC) at diffusion-weighted (DW) MRI is predictive of pathologic complete response (pCR) to neoadjuvant chemotherapy for breast cancer. Materials and Methods In this prospective multicenter study, 272 consecutive women with breast cancer were enrolled at 10 institutions (from August 2012 to January 2015) and were randomized to treatment with 12 weekly doses of paclitaxel (with or without an experimental agent), followed by 12 weeks of treatment with four cycles of anthracycline. Each woman underwent breast DW MRI before treatment, at early treatment (3 weeks), at midtreatment (12 weeks), and after treatment. Percentage change in tumor ADC from that before treatment (ΔADC) was measured at each time point. Performance for predicting pCR was assessed by using the area under the receiver operating characteristic curve (AUC) for the overall cohort and according to tumor hormone receptor (HR)/human epidermal growth factor receptor 2 (HER2) disease subtype. Results The final analysis included 242 patients with evaluable serial imaging data, with a mean age of 48 years ± 10 (standard deviation); 99 patients had HR-positive (hereafter, HR+)/HER2-negative (hereafter, HER2-) disease, 77 patients had HR-/HER2- disease, 42 patients had HR+/HER2+ disease, and 24 patients had HR-/HER2+ disease. Eighty (33%) of 242 patients experienced pCR. Overall, ΔADC was moderately predictive of pCR at midtreatment/12 weeks (AUC = 0.60; 95% confidence interval [CI]: 0.52, 0.68; P = .017) and after treatment (AUC = 0.61; 95% CI: 0.52, 0.69; P = .013). Across the four disease subtypes, midtreatment ΔADC was predictive only for HR+/HER2- tumors (AUC = 0.76; 95% CI: 0.62, 0.89; P < .001). In a test subset, a model combining tumor subtype and midtreatment ΔADC improved predictive performance (AUC = 0.72; 95% CI: 0.61, 0.83) over ΔADC alone (AUC = 0.57; 95% CI: 0.44, 0.70; P = .032.). Conclusion After 12 weeks of therapy, change in breast tumor apparent diffusion coefficient at MRI predicts complete pathologic response to neoadjuvant chemotherapy. © RSNA, 2018 Online supplemental material is available for this article.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*
,_underline_
or**bold**
. - Superscript can be denoted by
<sup>text</sup>
and subscript<sub>text</sub>
. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3.
, hyphens-
or asterisks*
. - Links can be included with:
[my link to pubmed](http://pubmed.com)
- Images can be included with:
![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
- For footnotes use
[^1](This is a footnote.)
inline. - Or use an inline reference
[^1]
to refer to a longer footnote elseweher in the document[^1]: This is a long footnote.
.